Nyxoah's Genio Therapy Receives Significant Medicare Reimbursement Boost for 2026.

Nyxoah's Genio Therapy has received significant 2026 Medicare reimbursement increases under the final CMS rule. The therapy will see a 48% rise in Hospital Outpatient Department reimbursement to approximately $45,000 and a 58% increase in Ambulatory Surgery Centers reimbursement to $42,373. This strengthens the economic foundation for therapy adoption across US hospital outpatient departments and ambulatory surgical centers.